Related Experiment Video
Updated: Jun 10, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials
Patrick Murray1, Gary W Chune, Vasudevan A Raghavan
1CardioMetabolic and Lipid Clinic Services, Scott and White/Texas A&M Health Sciences Center, Temple, TX, USA.
Abstract:
The United Kingdom Prospective Diabetes Study (UKPDS) and the Diabetes Chronic Complications Trial (DCCT) are two landmark trials that convincingly demonstrated that tight glycemic control has beneficial effects on microvascular end points. These studies also revealed a "legacy effect," which is a sustained benefit with respect to cardiovascular disease outcomes seen long after the conclusion of the trial. We discuss possible molecular mechanisms that could play a role in causing the legacy effect.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetic Nephropathy
Type II Diabetes II: Pathophysiology
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes: Symptoms, Diagnosis, and Complications